Nabriva Therapeutics AG recently announced new research findings for its lead product candidate lefamulin, the first pleuromutilin antibiotic available for systemic administration in humans. The company is developing both intravenous and ... Read more
Data from a Phase 2 clincial trial for solithromycin, a next-generation oral and intravenous fluoroketolide for the treatment of moderate to moderately-severe community acquired bacterial pneumonia (CABP) and urethritis, ... Read more
Cempra, Inc., announced that it has completed its rolling submission of a New Drug Application for solithromycin, a potential treatment for community-acquired bacterial pneumonia (CABP), to the U.S. Food and Drug Administration. The ... Read more
